SGLT2 Inhibitors Recommended for Treating CKD | ASHP Midyear
Denise Kelley, PharmD, BCPS, FASHP, discussed the efficacy of medications designed to treat the progression of chronic kidney disease.
From glucagon-like peptide-1s (GLP-1s) to non-steroidal mineralocorticoid receptor antagonists (nsMRAs), there are multiple variations of medications suited to treat chronic kidney disease (CKD). However, when it comes to the beginning of a CKD medication regimen, experts believe sodium-glucose cotransporter-2 (SGLT) inhibitors are the standard medications for patients with CKD.
“Specifically, canagliflozin (Invokana) has been FDA approved for diabetic kidney disease. Empagliflozin (Jardiance) and dapagliflozin (Farxiga) have been approved for [CKD] in general,” Denise Kelley, PharmD, BCPS, FASHP, told Drug Topics.
At the American Society of Health-System Pharmacists 2024 Midyear Clinical Meeting and Exhibition, held December 8 to 12 in New Orleans, Louisiana, Kelley gave a presentation titled “Nephr Give Up: Pharmacologic Strategies for Slowing Chronic Kidney Disease Progression.” She discussed the various medications approved for CKD and the specific opportunities for when patients can benefit from them.
After her presentation, Kelley caught up with Drug Topics to further discuss therapies that treat CKD. She also talked about the additional comorbidities that patients with CKD commonly experience, touching on the possible drug-drug interactions that accompany these patients.
Follow along with our coverage of the 2024 ASHP Midyear Clinical Meeting and Exhibition here.
Palliative Care Pharmacist Working to Improve Transitions of Care for Patients
December 10th 2024A conversation with Madison Irwin, PharmD, BCPS, clinical pharmacist specialist in palliative care at University of Michigan Health and a clinical assistant professor at the University of Michigan College of Pharmacy.
